Health and Healthcare

What to Look for in Amgen Earnings

Thinkstock

Amgen Inc. (NASDAQ: AMGN) is expected to report its second-quarter financial results after the markets close on Wednesday. In the most recent earnings report, this biotech giant beat estimates on both the top and bottom lines, but seemingly this was not enough for investors as shares were sent down for some time after that. However riding the most recent market rally since the Brexit vote, Amgen has recovered handily. The question about this earnings report is if it will head the same way as Gilead Sciences Inc. (NASDAQ: GILD) did earlier this week.

Thomson Reuters consensus estimates for Amgen call for $2.74 in earnings per share (EPS) on $5.58 billion in revenue. In the same period of last year, the company posted EPS of $2.57 and $5.37 billion in revenue.

Gilead reported its second-quarter financial results late Monday. In the report we saw weakening trends in the hepatitis C vaccine (HCV) segment, as well as slipping sales in other areas. Overall, the report was not good and investors took to dumping the stock.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives — similar to Gilead. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotech companies, reaching millions of patients around the world and developing a pipeline of medicines with breakaway potential.

A few analysts weighed in on Amgen prior to the earnings report:

  • Baird reiterated a Neutral rating with a $157 price target.
  • Merrill Lynch reiterated a Hold rating with a $182 price target.
  • Jefferies reiterated a Buy rating with a $187 price target.
  • BMO Capital Markets reiterated a Buy rating with a $186 price target.
  • Goldman Sachs reiterated a Buy rating.
  • Morgan Stanley reiterated an Overweight rating.
  • Sanford Bernstein initiated coverage with a Market Perform rating and a $161 target.

So far in 2016, Amgen has performed more or less in line with the broad markets, with the stock up over 5%. Over the past 52 weeks, the stock is only up about 4%.

Shares of Amgen were trading up 0.8% at $169.06 on Wednesday, with a consensus analyst price target of $184.12 and a 52-week trading range of $130.09 to $181.81.

Are You Ahead, or Behind on Retirement? (sponsor)

If you’re one of the over 4 Million Americans  set to retire this year, you may want to pay attention.

Finding a financial advisor who puts your interest first can be the difference between a rich retirement and barely getting by, and today it’s easier than ever. SmartAsset’s free tool matches you with up to three fiduciary financial advisors that serve your area in minutes. Each advisor has been carefully vetted, and must act in your best interests. Start your search now.

Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.